Silane-passivated silicon anode with PFAS-free polymer binder for lithium-ion batteries

Silicon anodes represent the most consequential materials upgrade available to lithium-ion cell manufacturers today: silicon's theoretical capacity is roughly ten times that of graphite, yet it has been commercially restrained for two decades by the twin problems of volumetric swelling and first-cycle irreversible capacity loss. The silane-passivated silicon anode platform addresses both vectors simultaneously — surface grafting with functional silanechemistry passivates the reactive silicon surface before electrolyte contact, while a PFAS-free polymeric binder replaces the legacy polyvinylidene fluoride system that is now under coordinated regulatory pressure across the EU, US, and UK. The regulatory timing here is not incidental. PFAS restrictions are creating a forced-substitution event for cell manufacturers who have historically relied on PVDF binders. That dependency is now a liability, and the window for locking in alternative binder chemistries with credible IP is narrow. This platform files into that window with a composition-form lead claim that explicitly carves out the PVDF-free design space, pairing the binder substitution with silane surface chemistry that independently suppresses the irreversible lithium consumption responsible for first-cycle coulombic efficiency losses. The combination is designed to work together: the silane layer is hypothesised to promote formation of a lithium-fluoride-rich solid-electrolyte interphase that is thinner, more conductive, and more mechanically compliant than the thick, organic-rich SEI that forms on unpassivated silicon surfaces, while the PFAS-free binder removes the regulatory overhang without sacrificing the electrode cohesion that silicon's volume excursions demand. This asset sits within the critical-mineral recovery and recycling separations portfolio as a supporting composition lead. Its role is explicitly that of a lead claim on a commercially addressable formulation, not a speculative breakthrough. The strategic value is the intersection of two converging pressures — performance physics and regulatory compliance — in a single filing that is computationally grounded and has a preliminary prior-art screen (not a freedom-to-operate opinion).

The core materials architecture combines silicon nanostructures — small enough to partially accommodate the roughly 300% volumetric expansion of lithiated silicon — with a monolayer of covalently grafted silane coupling agents. The silane chemistry is drawn from a defined set of functional variants: aminopropylsilane, glycidoxysilane, mercaptopropylsilane, and phosphonate-silane. Of these, the phosphonate-silane is mechanistically the most interesting: the phosphonate headgroup has a documented affinity for lithium-ion coordination and promotes nucleation of LiF-rich SEI domains during first-cycle lithiation. A LiF-rich SEI is mechanically harder, ionically conductive, and less prone to the continued solvent reduction that drives capacity fade in unpassivated silicon electrodes. The grafted silane monolayer also serves as a physical barrier that delays direct electrolyte contact during initial lithiation, giving the SEI nucleation sites time to organize into a more uniform film rather than the heterogeneous mosaic that forms on bare silicon surfaces. The binder selection spans polyacrylic acid, carboxymethyl cellulose, sodium alginate, polyimide, and styrene-butadiene rubber. This is not arbitrary breadth — each of these binders interacts with the silicon surface and the silane-modified interface differently. PAA and CMC form hydrogen bonds with residual silanol groups on the grafted surface and with the native silicon oxide, providing a chemical adhesion mechanism that survives repeated volume cycling. Alginate and SBR offer elastomeric compliance that absorbs the mechanical strain of volume excursion without delamination. Polyimide brings thermal stability relevant to higher-temperature operation. The combinatorial scope of the binder selection, paired with the silane chemistry variants, defines a structured composition space that the filing claims as a platform rather than a single point in formulation space. Computationally, this asset is grounded in silicon-surface molecular dynamics simulations that model the silane grafting process and the early-stage SEI formation dynamics at the functionalized interface. These are interface-focused MD trajectories, not bulk phonon calculations — the relevant physics here is surface chemistry and electrochemical reaction kinetics, not lattice dynamics. Separately, a first-cycle coulombic efficiency prediction (designated Simulation Example 18 in the supporting computational record) provides a predicted first-cycle CE above 88%, which is the target threshold for practical silicon-anode integration in high-energy cells. It is important to be precise: 88%+ is a simulation-derived prediction, not a measured experimental result. The phonon-stability multi-potential consensus workflow used for crystalline inorganic candidates does not apply here because this is a functionalized nanostructure-polymer composite, not a periodic crystal — the relevant computational validation is surface-chemistry simulation, and that is what has been performed. The negative limitations built into the claim architecture are technically meaningful, not merely defensive. The explicit exclusion of PVDF as a binder and the exclusion of broad-scope silane coupling agents without the specified functional groups narrows the claim to the specific combination that the computational work supports, and simultaneously positions the patent directly in the regulatory carve-out space where PVDF substitution is being driven. These limitations ensure the claim reads on the commercially relevant combination while reducing prior-art exposure from the large body of literature on silane-treated oxide surfaces and commodity binder systems.

The addressable market for this technology is the silicon-anode segment of the lithium-ion battery industry, estimated at $1-3 billion based on current silicon-anode materials and electrode supply projections. This estimate reflects the subset of the broader lithium-ion cell market where silicon anode content is commercially active or in advanced qualification — primarily high-energy cylindrical cells for electric vehicles and high-capacity consumer electronics batteries. The figure is an estimate and should be treated as an order-of-magnitude reference rather than a precise market model. Growth in this segment is tied to the rate of silicon content increase in mainstream EV cells, which is accelerating as cell makers push toward the 300+ Wh/kg cell energy density targets that graphite alone cannot reach. The buyers are anode material suppliers and cell manufacturers. Anode material companies — those producing silicon nanoparticles, silicon-graphite composites, or silicon-dominant electrode materials — are the most direct licensees because the silane grafting step would be integrated into their particle surface treatment process. Cell manufacturers operating vertically integrated electrode lines are a second category, particularly those under procurement pressure to qualify PFAS-free electrode materials ahead of regulatory enforcement dates. The royalty logic for a composition patent in this space typically follows a per-kilogram-of-active-material or per-cell structure, with licensing terms negotiated against the cost delta between the PFAS-free formulation and the incumbent PVDF system. Given that PFAS compliance is becoming a regulatory requirement rather than a performance differentiator, the licensing leverage is upstream of ordinary performance-based royalty negotiations: the licensee needs a PFAS-free solution regardless of small performance trade-offs. The PFAS regulatory window is the key timing variable. The EU's PFAS restriction under REACH, US EPA regulatory actions, and UK PFAS policy are all creating hard compliance deadlines that translate into qualified-alternative procurement timelines for cell manufacturers. Those timelines compress the window during which a PFAS-free binder + surface passivation composition patent can extract licensing value, but also accelerate the demand signal. A filing that is clean, claims the right formulation space, and is supported by computational evidence of mechanism is positioned to be a necessary license rather than a discretionary one during this transition.

suppresses first-cycle irreversible loss + PFAS-free binder for regulatory headroom

silane-grafted Si + PFAS-free binder combination; PVDF binder excluded

Preliminary screen only. This is not a freedom-to-operate opinion.

The most direct acquirers or licensees for this asset are silicon anode material suppliers — companies that supply silicon nanoparticles, silicon-graphite composites, or silicon-dominant anode materials to cell manufacturers. These companies control the surface treatment step where silane grafting would be integrated, and they have commercial motivation to offer a PFAS-compliant anode material with a predicted first-cycle CE advantage, still to be shown in bench data, and claims that would cover it if granted. Names in this space include established silicon anode specialists as well as the materials subsidiaries of large battery manufacturers pursuing vertical integration. The second buyer category is cell manufacturers operating electrode lines who are under direct regulatory pressure to qualify PFAS-free electrode formulations — for these buyers, a licensed composition patent provides both the formulation guidance and the IP clearance needed to qualify a new anode system with automotive or consumer electronics customers who themselves require supply-chain PFAS compliance documentation. A third consideration is strategic defensive acquisition by incumbents who currently sell PVDF binder or PVDF-based electrode systems and want to own the transition pathway their customers will need. For a PVDF binder supplier facing regulatory-driven demand destruction, acquiring or licensing the PFAS-free alternative composition gives them a managed transition offering rather than a market exit. This is a well-established pattern in regulated materials markets and should be considered a plausible, if less obvious, buyer profile. The asset is most valuable in a licensing structure given the composition-patent form, but outright acquisition makes sense for a buyer seeking to control the PFAS-transition narrative in the silicon anode supply chain.

The primary risk is the open experimental validation gate. The predicted first-cycle CE above 88% is a simulation-derived number, and until bench-level half-cell or full-cell data is in hand, the claim lacks the empirical support that would make it most defensible in prosecution and most compelling in a licensing negotiation. This risk is bounded — the experiment is well-defined and uses standard battery characterization protocols — but it is real. A buyer acquiring this asset pre-validation accepts the simulation prediction as sufficient basis, which may be appropriate given the mechanistic grounding of the surface MD work, but the risk profile changes materially once coupon data is available. The roadmap to de-risk is straightforward: fabricate electrodes using the silane-grafted silicon with each of the specified PFAS-free binders, run first-cycle CE measurements and 50-100 cycle retention tests in half-cell configuration, and compare against the PVDF baseline. That data set both validates the filing and creates the experimental examples needed to strengthen prosecution. A secondary risk is the competitive pace of the PFAS-free binder transition. If large cell manufacturers or their Tier 1 suppliers file their own PFAS-free binder composition patents — or if the FDA/EPA/REACH regulatory timeline slips and the compliance deadline pressure eases — the forced-substitution dynamic that gives this filing its commercial urgency could weaken. The silane-passivation element of the claim provides a performance-based value proposition that exists independent of the regulatory driver, but the regulatory urgency is what makes the licensing window actionable in the near term. Monitoring the regulatory timeline and competing filings in the binder space is the appropriate ongoing diligence posture for any buyer.